Related Experiment Video
Updated: Jan 3, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
HBV Genome and Life Cycle
Jie Wang1, Hongxin Huang1, Yongzhen Liu1
1Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, P.R. China.
Insights
Chronic hepatitis B (CHB) is a major public health concern. New therapies targeting the hepatitis B virus (HBV) life cycle and novel biomarkers offer future hope for CHB treatment and cure.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Chronic hepatitis B virus (HBV) infection is a significant global health issue, leading to severe liver conditions like cirrhosis and hepatocellular carcinoma.
- Current treatments, including nucleos(t)ide analogues (NA) and pegylated interferon-α (Peg-IFNα), inhibit HBV replication but rarely achieve a complete cure, necessitating long-term therapy.
Purpose of the Study:
- To explore novel antiviral strategies for chronic hepatitis B (CHB) by understanding the complete HBV life cycle.
- To identify potential new therapeutic targets and biomarkers for monitoring treatment efficacy in CHB patients.
Main Methods:
- Review of recent advancements in understanding the hepatitis B virus (HBV) life cycle.
- Investigation of the role of the sodium-taurocholate cotransporting polypeptide (NTCP) as the functional receptor for HBV entry.
- Analysis of newly identified HBV components released into circulation, such as immature nucleocapsids and empty particles.
Main Results:
- The discovery of the HBV functional receptor, sodium-taurocholate cotransporting polypeptide (NTCP), on hepatocytes.
- Identification of circulating immature nucleocapsids, nucleocapsids with double-strand linear DNA (dslDNA), and empty HBV particles.
- Elucidation of previously unknown steps in the HBV life cycle.
Conclusions:
- A comprehensive understanding of the HBV life cycle provides new avenues for developing targeted antiviral therapies.
- Emerging HBV markers in circulation may serve as future tools for assessing the effectiveness of antiviral treatments in CHB patients.
- Novel therapeutic approaches targeting specific stages of the viral life cycle hold promise for achieving a functional cure for CHB.
Abstract:
Chronic hepatitis B virus (HBV) infection remains to be a serious threat to public health and is associated with many liver diseases including chronic hepatitis B (CHB), liver cirrhosis, and hepatocellular carcinoma. Although nucleos(t)ide analogues (NA) and pegylated interferon-α (Peg-IFNα) have been confirmed to be efficient in inhibiting HBV replication, it is difficult to eradicate HBV and achieve the clinical cure of CHB. Therefore, long-term therapy has been recommended to CHB treatment under the current antiviral therapy. In this context, the new antiviral therapy targeting one or multiple critical steps of viral life cycle may be an alternative approach in future. In the last decade, the functional receptor [sodium-taurocholate cotransporting polypeptide (NTCP)] of HBV entry into hepatocytes has been discovered, and the immature nucleocapsids containing the non- or partially reverse-transcribed pregenomic RNA, the nucleocapsids containing double-strand linear DNA (dslDNA), and the empty particles devoid of any HBV nucleic acid have been found to be released into circulation, which have supplemented the life cycle of HBV. The understanding of HBV life cycle may offer a new instruction for searching the potential antiviral targets, and the new viral markers used to monitor the efficacy of antiviral therapy for CHB patients in the future.
Related Concept Videos
Retrovirus Life Cycles
Size and Structure of Viral Genomes
Lytic Cycle of Bacteriophages
Lysogenic Cycle of Bacteriophages
Viruses with RNA Genomes
Viral Replication: Lysogenic Cycle

